Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice

To evaluate medical and surgical treatment of postbariatric hypoglycaemia (PBH) in daily practice.

[1]  M. Zanella,et al.  SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery , 2022, Obesity Surgery.

[2]  M. Patti,et al.  Pramlintide for post‐bariatric hypoglycaemia , 2022, Diabetes, obesity & metabolism.

[3]  Felix Wortmann,et al.  The impact of postbariatric hypoglycaemia on driving performance: A randomized, single‐blind, two‐period, crossover study in a driving simulator , 2021, Diabetes, obesity & metabolism.

[4]  R. Simó,et al.  Canagliflozin: A New Therapeutic Option in Patients That Present Postprandial Hyperinsulinemic Hypoglycemia after Roux-en-Y Gastric Bypass: A Pilot Study , 2021, Obesity Facts.

[5]  T. McLaughlin,et al.  PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia , 2021, The Journal of clinical endocrinology and metabolism.

[6]  L. You,et al.  Surgical Treatment for Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass: a Literature Review , 2021, Obesity Surgery.

[7]  T. McLaughlin,et al.  Guidelines for gastrostomy tube placement and enteral nutrition in patients with severe, refractory hypoglycemia after gastric bypass. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[8]  A. V. van Beek,et al.  Cholecystectomy increases the risk of dumping syndrome and postbariatric hypoglycemia after bariatric surgery. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[9]  P. Ritz,et al.  International consensus on the diagnosis and management of dumping syndrome , 2020, Nature Reviews Endocrinology.

[10]  J. Holst,et al.  A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals , 2019, Obesity Surgery.

[11]  J. Holst,et al.  Postprandial hypoglycaemia after Roux‐en‐Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide , 2019, Diabetes, obesity & metabolism.

[12]  J. Himpens,et al.  Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018 , 2018, Obesity Surgery.

[13]  M. Patti,et al.  Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies , 2018, The Journal of clinical endocrinology and metabolism.

[14]  S. Bhoyrul,et al.  Safety and efficacy of pasireotide in dumping syndrome—results from a phase 2, multicentre study , 2018, Alimentary pharmacology & therapeutics.

[15]  B. Wolffenbuttel,et al.  The short- to mid-term symptom prevalence of dumping syndrome after primary gastric-bypass surgery and its impact on health-related quality of life. , 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[16]  G. Finlayson,et al.  Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity , 2017, Diabetes, obesity & metabolism.

[17]  A. Lecube,et al.  Hyperinsulinemic Hypoglycemia after Bariatric Surgery: Diagnosis and Management Experience from a Spanish Multicenter Registry , 2016, Obesity Facts.

[18]  A. P. Beek,et al.  Diagnostic tools for post‐gastric bypass hypoglycaemia , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[19]  J. Mordes,et al.  Evaluation, Medical Therapy, and Course of Adult Persistent Hyperinsulinemic Hypoglycemia After Roux-en-Y Gastric Bypass Surgery: A Case Series. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[20]  J. Apers,et al.  Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide: a comparison with octreotide on insulin, glucagon, and GLP-1. , 2014, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[21]  M. Sundbom,et al.  GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication? , 2013, European journal of endocrinology.

[22]  B. Quintana,et al.  Post-gastric-bypass hypoglycemia successfully treated with alpha-glucosidase inhibitor therapy. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[23]  A. González-González,et al.  Use of diazoxide in management of severe postprandial hypoglycemia in patient after Roux-en-Y gastric bypass. , 2013, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[24]  T. Funahashi,et al.  Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes , 2012, Cardiovascular Diabetology.

[25]  P. Ritz,et al.  Usefulness of acarbose and dietary modifications to limit glycemic variability following Roux-en-Y gastric bypass as assessed by continuous glucose monitoring. , 2012, Diabetes technology & therapeutics.

[26]  J. Lagergren,et al.  Population‐based study of the need for cholecystectomy after obesity surgery , 2012, The British journal of surgery.

[27]  J. Holst,et al.  Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue. , 2012, European journal of endocrinology.

[28]  J. Holst,et al.  Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects , 2012, Obesity Surgery.

[29]  A. Maíz,et al.  Acarbose Improves Hypoglycaemia Following Gastric Bypass Surgery Without Increasing Glucagon-Like Peptide 1 Levels , 2012, Obesity Surgery.

[30]  D. Farley,et al.  Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreatogenous hypoglycemia from diffuse islet cell disease. , 2010, Surgery.

[31]  F. Rasmussen,et al.  Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986–2006 in Sweden , 2010, Diabetologia.

[32]  J. Holst,et al.  Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. , 2010, The Journal of clinical endocrinology and metabolism.

[33]  P. Ritz,et al.  Usefulness of Continuous Glucose Monitoring for the Diagnosis of Hypoglycemia after a Gastric Bypass in a Patient Previously Treated for Type 2 Diabetes , 2010, Obesity surgery.

[34]  C. Gragnoli,et al.  Successful Medical Management of Status Post-Roux-en-Y-Gastric-Bypass Hyperinsulinemic Hypoglycemia , 2009, Obesity surgery.

[35]  R. Bisschops,et al.  Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  W. Coutinho,et al.  Post-prandial Hypoglycemia after Bariatric Surgery: Pharmacological Treatment with Verapamil and Acarbose , 2008, Obesity surgery.

[37]  P. Didden,et al.  Octreotide therapy in dumping syndrome: analysis of long‐term results , 2006, Alimentary pharmacology & therapeutics.

[38]  J. Hansen.  Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. , 2006, Current medicinal chemistry.

[39]  J. Vecht,et al.  Long‐term results of octreotide‐therapy in severe dumping syndrome , 1999, Clinical endocrinology.

[40]  W. Hasler,et al.  Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. , 1996, The Journal of pharmacology and experimental therapeutics.

[41]  S. Mulvihill,et al.  Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. , 1991, Archives of surgery.

[42]  N. Abumrad,et al.  Efficacy of Octreotide Acetate in Treatment of Severe Postgastrectomy Dumping Syndrome , 1990, Annals of surgery.

[43]  Z. Tulassay,et al.  Long acting somatostatin analogue in dumping syndrome , 1989, The British journal of surgery.

[44]  D. Johnston,et al.  Somatostatin analogue SMS 201–995 (octreotide) as a possible solution to the dumping syndrome after gastrectomy or vagotomy , 1989, British Journal of Surgery.

[45]  J. Reynard,et al.  Long-term symptomatic relief of postprandial hypoglycaemia following gastric surgery with a somatostatin analogue. , 1989, Postgraduate medical journal.

[46]  C. Lamers,et al.  Treatment of the Dumping Syndrome with the Somatostatin Analogue SMS 201–995 , 1988, Annals of Surgery.

[47]  J. Jansen,et al.  Effect of acarbose, pectin, a combination of acarbose with pectin, and placebo on postprandial reactive hypoglycaemia after gastric surgery. , 1983, Gut.

[48]  M. Alam,et al.  A GLYCOSIDE-HYDROLASE INHIBITOR IN TREATMENT OF DUMPING SYNDROME , 1979, The Lancet.